REFERENCES
- Parkin DM, Bray F, Ferlay J, Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
- Vivarelli M, Guglielmi A, Ruzzenente A, Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102–107.
- Fan ST, Lo CM, Liu CL, Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322–330.
- Liu CL, Fan ST, Cheung ST, Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg. 2006;244:194–203.
- Lai EC, Fan ST, Lo CM, Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291–298.
- Lau H, Fan ST, Ng IO, Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998;83:2302–2311.
- Adachi E, Maehara S, Tsujita E, Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 2002;131:S148–S152.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
- Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J. 2008;14:1–6.
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–531.
- Dews M, Homayouni A, Yu D, Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060–1065.
- Calin GA, Sevignani C, Dumitru CD, Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.
- Calin GA, Ferracin M, Cimmino A, A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–1801.
- He L, Thomson JM, Hemann MT, A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–833.
- Li H, Bian C, Liao L, miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat. 2011;126:565–575.
- Tsujiura M, Ichikawa D, Komatsu S, Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174–1179.
- Ebi H, Sato T, Sugito N, Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009;28:3371–3379.
- Yang F, Yin Y, Wang F, miR-17-5p promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 2010;51:1614–1623.
- Yao J, Liang L, Huang S, MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010;51:846–856.
- Matsubara H, Takeuchi T, Nishikawa E, Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007;26(41):6099–6105.
- Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006;26:8191–8201.
- Takakura S, Mitsutake N, Nakashima M, Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008;99:1147–1154.
- Murakami Y, Yasuda T, Saigo K, Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537–2545.
- Fujita H, Yu J, Ohuchida K, MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 2010;10:748–757.
- Poon RT, Fan ST, Ng IO, Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500–507.
- Shimada K, Sano T, Sakamoto Y, A long term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer 2005;104:1939–1947.
- Farinati F, Rinaldi M, Gianni S, How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266– 2273.
- Park JH, Koh KC, Choi MS, Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg. 2006;192:29–33.
- Landi MT, Zhao Y, Rotunno M, MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16:430–441.
- Xiong Y, Fang JH, Yun JP, Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836–845.
- Ng EK, Chong WW, Jin H, Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375–1381.
- Cheng Y, Tan N, Yang J, A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci. 2010;119:87–95.
- Mitchell PS, Parkin RK, Kroh EM, Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–10518.